W Law1, C Johnson2, M Rushton1, S Dent3. 1. Faculty of Medicine. 2. Division of Cardiology, Department of Medicine, and. 3. Division of Medical Oncology, Department of Medicine, University of Ottawa, Ottawa, ON.
Abstract
INTRODUCTION: Patients with breast cancer (bca) who overexpress her2 (the human epidermal growth factor receptor 2) are at risk for cardiotoxicity when treated with anthracycline-based chemotherapy and her2-targeted agents. The Framingham risk score (frs) is a validated tool that stratifies patients into high-, intermediate-, or low-risk groups and calculates their 10-year risk of developing cardiovascular disease (cvd) based on past medical history, systolic blood pressure, and measurement of serum lipids. We retrospectively analyzed patients with her2-positive bca to determine whether the frs predicts adverse cardiovascular (CV) events or cardiotoxicity in patients treated using anthracyclines or her2-targeted therapy, or both. METHODS: The frs was determined for patients with bca referred to The Ottawa Hospital Cardiology-Oncology Clinic from October 2008 to August 2014. The patients were stratified into high (≥20%), intermediate (10%-20%), and low (<10%) 10-year cv risk groups. Primary outcomes included cvd-related hospitalizations and deaths, and cardiotoxicity [drop in left ventricular ejection fraction (lvef) of >10% to a lvef ≤50%]. RESULTS: Of the 152 patients included in the analysis (median follow-up: 40.7 months; range: 3.5-263 months), 47 (31%) were classified as high risk; 36 (24%), as intermediate risk; and 69 (45%), as low-risk. The number of cvd-related hospitalizations and deaths was 22, for an overall prevalence of 14%, with significantly more events occurring in high-risk than in low-risk patients (odds ratio: 4.18; 95% confidence limits: 1.47, 11.89). The frs predicted a 10-year risk of any cv event of 11.2% and underestimated the actual rate of cv events in the entire cohort. High frs was not associated with cardiotoxicity (p = 0.82). CONCLUSIONS: In a population of patients with her2-positive bca referred to a cardiology-oncology clinic, the frs does not accurately predict the risk of cv events or cardiotoxicity.
INTRODUCTION:Patients with breast cancer (bca) who overexpress her2 (the humanepidermal growth factor receptor 2) are at risk for cardiotoxicity when treated with anthracycline-based chemotherapy and her2-targeted agents. The Framingham risk score (frs) is a validated tool that stratifies patients into high-, intermediate-, or low-risk groups and calculates their 10-year risk of developing cardiovascular disease (cvd) based on past medical history, systolic blood pressure, and measurement of serum lipids. We retrospectively analyzed patients with her2-positive bca to determine whether the frs predicts adverse cardiovascular (CV) events or cardiotoxicity in patients treated using anthracyclines or her2-targeted therapy, or both. METHODS: The frs was determined for patients with bca referred to The Ottawa Hospital Cardiology-Oncology Clinic from October 2008 to August 2014. The patients were stratified into high (≥20%), intermediate (10%-20%), and low (<10%) 10-year cv risk groups. Primary outcomes included cvd-related hospitalizations and deaths, and cardiotoxicity [drop in left ventricular ejection fraction (lvef) of >10% to a lvef ≤50%]. RESULTS: Of the 152 patients included in the analysis (median follow-up: 40.7 months; range: 3.5-263 months), 47 (31%) were classified as high risk; 36 (24%), as intermediate risk; and 69 (45%), as low-risk. The number of cvd-related hospitalizations and deaths was 22, for an overall prevalence of 14%, with significantly more events occurring in high-risk than in low-risk patients (odds ratio: 4.18; 95% confidence limits: 1.47, 11.89). The frs predicted a 10-year risk of any cv event of 11.2% and underestimated the actual rate of cv events in the entire cohort. High frs was not associated with cardiotoxicity (p = 0.82). CONCLUSIONS: In a population of patients with her2-positive bca referred to a cardiology-oncology clinic, the frs does not accurately predict the risk of cv events or cardiotoxicity.
Entities:
Keywords:
Cardio-oncology; Framingham risk score; breast cancer; cardiotoxicity; her2; trastuzumab
Authors: Michael Poullis; James McShane; Matthew Shaw; Richard Page; Michael Shackcloth; Neeraj Mediratta Journal: Asian Cardiovasc Thorac Ann Date: 2012-02
Authors: Elizabeth Tan-Chiu; Greg Yothers; Edward Romond; Charles E Geyer; Michael Ewer; Deborah Keefe; Richard P Shannon; Sandra M Swain; Ann Brown; Louis Fehrenbacher; Victor G Vogel; Thomas E Seay; Priya Rastogi; Eleftherios P Mamounas; Norman Wolmark; John Bryant Journal: J Clin Oncol Date: 2005-11-01 Impact factor: 44.544
Authors: Sara B Jones; Gwendolyn A Thomas; Sara D Hesselsweet; Marty Alvarez-Reeves; Herbert Yu; Melinda L Irwin Journal: Cancer Prev Res (Phila) Date: 2012-12-04
Authors: Todd J Anderson; Jean Grégoire; Robert A Hegele; Patrick Couture; G B John Mancini; Ruth McPherson; Gordon A Francis; Paul Poirier; David C Lau; Steven Grover; Jacques Genest; André C Carpentier; Robert Dufour; Milan Gupta; Richard Ward; Lawrence A Leiter; Eva Lonn; Dominic S Ng; Glen J Pearson; Gillian M Yates; James A Stone; Ehud Ur Journal: Can J Cardiol Date: 2013-02 Impact factor: 5.223
Authors: Joerg Herrmann; Amir Lerman; Nicole P Sandhu; Hector R Villarraga; Sharon L Mulvagh; Manish Kohli Journal: Mayo Clin Proc Date: 2014-09 Impact factor: 7.616
Authors: S Romano; S Fratini; E Ricevuto; V Procaccini; G Stifano; M Mancini; M Di Mauro; C Ficorella; M Penco Journal: Br J Cancer Date: 2011-11-08 Impact factor: 7.640
Authors: Erin J Aiello Bowles; Robert Wellman; Heather Spencer Feigelson; Adedayo A Onitilo; Andrew N Freedman; Thomas Delate; Larry A Allen; Larissa Nekhlyudov; Katrina A B Goddard; Robert L Davis; Laurel A Habel; Marianne Ulcickas Yood; Catherine McCarty; David J Magid; Edward H Wagner Journal: J Natl Cancer Inst Date: 2012-09-05 Impact factor: 13.506
Authors: Roberta Florido; Alexandra K Lee; John W McEvoy; Ron C Hoogeveen; Silvia Koton; Mara Z Vitolins; Chetan Shenoy; Stuart D Russell; Roger S Blumenthal; Chiadi E Ndumele; Christie M Ballantyne; Corinne E Joshu; Elizabeth A Platz; Elizabeth Selvin Journal: Am J Epidemiol Date: 2019-12-31 Impact factor: 4.897
Authors: Husam Abdel-Qadir; Paaladinesh Thavendiranathan; Peter C Austin; Douglas S Lee; Eitan Amir; Jack V Tu; Kinwah Fung; Geoffrey M Anderson Journal: J Natl Cancer Inst Date: 2019-08-01 Impact factor: 13.506